Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
2019
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Glutamate receptor ion channels
2005 Standout
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
2003
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
2010
Current management strategies and emerging treatments for functional dyspepsia
2013
Parkinson's disease
2021 Standout
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
Methods for Predicting Human Drug Metabolism
2006
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
2007
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Double‐Dose, New‐Generation Proton Pump Inhibitors Do Not Improve Helicobacter pylori Eradication Rate
2007
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
2009
Pharmacokinetics of Ropivacaine in Uremic and Nonuremic Patients After Axillary Brachial Plexus Block
2003
Perioperative Management of Antithrombotic Therapy
2012 Standout
Oral Anticoagulant Therapy
2012 Standout
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation
2006
Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac
2013
Kyoto global consensus report onHelicobacter pylorigastritis
2015 Standout
Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains
1999 StandoutNobel
Esomeprazole-Based Helicobacter Pylori Eradication Therapy and The Effect of Antibiotic Resistance: Results of Three Us Multicenter, Double-Blind Trials
2000
DrugBank: a knowledgebase for drugs, drug actions and drug targets
2007 Standout
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Stroke
2008 Standout
Microfluidic organs-on-chips
2014 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Esomeprazole — enhanced bio‐availability, specificity for the proton pump and inhibition of acid secretion
2003
New Anticoagulant Agents: Direct Thrombin Inhibitors
2008
Prevention of Venous Thromboembolism
2004 Standout
Antithrombotic Therapy in Atrial Fibrillation
2004
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
2018 Standout
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
2009
H pylori antibiotic resistance: prevalence, importance, and advances in testing
2004 Standout
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
2009
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
2005
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Helicobacter pyloriInfection
2002 Standout
Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review
2016
Normal and Pathologic Concentrations of Uremic Toxins
2012 Standout
Prevention of Venous Thromboembolism
2008 Standout
Effects of the substituted (S)-3-phenylpiperidine (?)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity
1998 StandoutNobel
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases
2005
Comparative Pharmacokinetics of Vitamin K Antagonists
2005
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls
2003
Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms
1998
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole
2004
Design and Development of Molecular Imaging Probes
2010
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
2015 StandoutNobel
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Antithrombotic Therapy in Atrial Fibrillation
2008
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Pharmacokinetics of Ropivacaine in Uremic and Nonuremic Patients After Axillary Brachial Plexus Block
2003
Management of Parkinson's disease: An evidence-based review
2002
Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease
2000
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
2003
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY
2005
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
2007 Standout
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
2005
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2005
The Adaptive Brain: Aging and Neurocognitive Scaffolding
2008 Standout
Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice
2011 StandoutNobel
Works of Eva Bredberg being referenced
4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicin
2008
Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions
2003
AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES
2004
Dose finding study of mosapride in functional dyspepsia: a placebo‐controlled, randomized study
2002
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
2000
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
2001
Cerebral uptake and utilization of therapeutic [β-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response
1992
Pharmacokinetics of Levodopa and Carbidopa in Rats Following Different Routes of Administration
1994
Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease
1993
Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
2008
Metabolism and excretion of ropivacaine in humans.
1996
Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
2000
Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E)
2000